Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan 17;217(3):494-497.
doi: 10.1093/infdis/jix564.

Immunogenicity and Safety of Yellow Fever Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients After Withdrawal of Immunosuppressive Therapy

Flore Sicre de Fontbrune  1 , Cécile Arnaud  2 , Morgane Cheminant  3 , Aude Boulay  4 , Johana Konopacki  5 , Simona Lapusan  6 , Christine Robin  7 , Françoise Bernaudin  2 , Felipe Suarez  3 , François Simon  4 , Gérard Socié  1 , Nathalie Colin de Verdière  8 , Paul-Henri Consigny  9
Affiliations

Immunogenicity and Safety of Yellow Fever Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients After Withdrawal of Immunosuppressive Therapy

Flore Sicre de Fontbrune et al. J Infect Dis. .

Abstract

As a live attenuated vaccine, yellow fever vaccine (YFV) is not routinely performed after allogeneic hematopoietic stem cell transplant (HSCT) despite it being the only efficient preventive therapy. We retrospectively identified 21 HSCT recipients immunized with YFV at a median of 39 months after HSCT and a median of 33 months after withdrawal of immunosuppression without any side effects. Eighteen evaluable patients had protective immunity after YFV. We also observed that a third of the recipients vaccinated with YFV before HSCT had persistent protective immunity after HSCT.

Keywords: allogeneic transplantation; immunocompromised; live attenuated vaccine; yellow fever.

PubMed Disclaimer

Comment in

MeSH terms

LinkOut - more resources